» Articles » PMID: 3801290

Anthracycline-induced Inhibition of Membrane Permeability Functions Dependent on Metabolic Energy

Overview
Journal Br J Cancer
Specialty Oncology
Date 1986 Dec 1
PMID 3801290
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

The influence of anthracyclines on membrane permeability functions has been investigated in HeLa cells by monitoring the efflux of fluorescein. Release of the fluorescent dye, dependent on the metabolic energy supply, occurs after the intracellular accumulation and enzymatic hydrolysis of the non-fluorescent substrate fluorescein diacetate (FDA). Flow cytometric evaluation of the efflux kinetics showed that adriamycin (ADR), N-trifluoroacetyladriamycin-14-valerate (AD-32) and daunorubicin (DNR) inhibited the permeability process. The degree of inhibition was dependent, though to different extent, on the intracellular concentration of each drug. An increase in the efflux rate was always observed when the cells were treated with the drugs in the presence of 20 mM glucose. Relationship of these effects with energetic metabolism was supported by the finding that ATP levels were lowered by the drugs and increased by glucose. Evaluation of the cytotoxicity induced by each drug showed that the intracellular amount necessary to inhibit cell survival by 50% was of the same order of magnitude as that which decreases to 50% membrane permeability to fluorescein. These results indicate a correspondence in the concentrations of anthracyclines required for inducing cytotoxicity and for inhibiting membrane permeability functions dependent on the metabolic energy supply.

Citing Articles

Intracellular turnover of fluorescein diacetate. Influence of membrane ionic gradients on fluorescein efflux.

Prosperi E Histochem J. 1990; 22(4):227-33.

PMID: 2387757 DOI: 10.1007/BF02386009.


Monoclonal antibody L6-daunomycin conjugates constructed to release free drug at the lower pH of tumor tissue.

Lavie E, Hirschberg D, Schreiber G, Thor K, Hill L, Hellstrom I Cancer Immunol Immunother. 1991; 33(4):223-30.

PMID: 2059966 PMC: 11038951. DOI: 10.1007/BF01744941.


Adriamycin-induced inhibition of arachidonate incorporation into phospholipids of mastocytoma P815 cells.

Kondakova I, Vereschagina S, Borunov E Cancer Chemother Pharmacol. 1992; 31(1):79-80.

PMID: 1458564 DOI: 10.1007/BF00695999.

References
1.
Sengbusch G, Couwenbergs C, Kuhner J, Muller U . Fluorogenic substrate turnover in single living cells. Histochem J. 1976; 8(4):341-50. DOI: 10.1007/BF01003822. View

2.
Ferrero M, Ferrero E, Gaja G, Bernelli-Zazzera A . Adriamycin: energy metabolism and mitochondrial oxidations in the heart of treated rabbits. Biochem Pharmacol. 1976; 25(2):125-30. DOI: 10.1016/0006-2952(76)90278-1. View

3.
Sontag W . A comparative kinetic study on the conversion of fluoresceindiacetate to fluorescein in living cells and in vitro. Radiat Environ Biophys. 1977; 14(1):1-12. DOI: 10.1007/BF01331024. View

4.
Folkers K, Liu M, Watanabe T, Porter T . Inhibition by adriamycin of the mitochondrial biosynthesis of coenzyme Q10 and implication for the cardiotoxicity of adriamycin in cancer patients. Biochem Biophys Res Commun. 1977; 77(4):1536-42. DOI: 10.1016/s0006-291x(77)80152-6. View

5.
Baisch H . Effects of X-rays on cell membranes. II. Changes of permeability measured by fluorescein efflux. Radiat Environ Biophys. 1978; 15(3):221-8. DOI: 10.1007/BF02176791. View